A lot of different early and late complications may occur after liver transplantation. They could be related to surgical procedure, to infectious diseases or immuno-mediated diseases (acute cellular rejection, ACR). Almost all of those complications are characterized by an elevation in liver enzymes (ALT, AST and GGT) and a decline of liver function tests (serum bilirubin and INR increase) possibly leading to early allograft disfunction (EAD). In this scenario there is a lack of biomarker that could predict the development of ACR and/or EAD.
The aim of this study is to explore the prognostic role of non-invasive instrumental and biological marker in the early post-transplant phase.
Patients eligible for liver transplantation following National and International Guidelines
No agreement or inability to give informed consent
Re-transplant patients
Liver transplant in fulminant hepatitis